Table 2.
The effects of Honaucin A derivatives on cell viability, TRAP activity and IC50 in RANKL-induced Osteoclastogenesis.
| Compound | Cell viability (0.5 μg/ml)
|
TRAP (%) | TRAP (%) | IC50 (μg/ml) | |
|---|---|---|---|---|---|
| Day 1 | Day 3 | 0.1 μg/ml | 0.5μg/ml | ||
| Honaucin A | 106.20 | 93.40 | 69.03 ± 4 | 59.63 ± 1.1 | 0.63 ± 0.09 |
| Hex-Honaucin A | 102.41 | 91.81 | 64.01 ± 1.9 | 47.28 ± 1.8 | 0.68 ± 0.09 |
| Br-Honaucin A | 103.27 | 96.55 | 45.18 ± 2.6 | 40.58 ± 1.8 | 0.54 ± 0.06 |
| I-Honaucin A | 98.79 | 86.90 | 59.83 ± 3.4 | 46.02 ± 2.9 | 0.61± 0.09 |
Cell viability was measured by MTT assay in RAW 264.7 cells upon treatment with individual compounds at 0.5 μg/ml final concentrations for 1 day and 3 days. Cell viability represents the percentage of the control. Relative TRAP activity of individual compounds at 0.1 μg/ml and 0.5 μg/ml in the presence of 50 μg/ml RANKL. IC50 was calculated for TRAP activity. Values are expressed as means ± S.D. of triplicate experiments